Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Rituximab, a monoclonal antibody targeting the CD20 antigen, depletes CD20-positive B lymphocytes through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and programmed cell death (PD), providing a robust rationale for its use in treating SLE (114, 115)
Causal effect of exogenous antioxidants on the risk of the six cancers After Bonferroni correction, no significant causal association was found between exogenous antioxidants and the six cancers (Figure 5)
Vitamin E & Other Nutrients: Provides additional skin health support
Patients who want accelerated tissue repair and reduced inflammation over a protocol cycle are well matched
